Literature DB >> 22863407

Effects of psyllium on metabolic syndrome risk factors.

Sebely Pal1, Simone Radavelli-Bagatini.   

Abstract

High-fibre intake has been shown to reduce the risk of metabolic syndrome (MS), cardiovascular disease and type 2 diabetes. Psyllium is one of the most widely used fibre supplements because it is reasonably cheap and is better tolerated than other fibre supplements. The review of the literature supports the notion that the consumption of psyllium provides benefits to many components of the MS. Psyllium supplementation does improve glucose levels and insulin response, blood pressure, as well as lipid profile in both animals and humans, thereby reducing metabolic risk factors. Appetite has also been reported to decrease after the consumption of psyllium in most studies. Collectively, psyllium supplementation could be promoted to patients who present MS risk factors, such as hypercholesterolaemia, hypertriglyceridaemia and hyperglycaemia. It may also play a role in controlling body weight, body composition, appetite and hypertension, but further investigation is still required.
© 2012 The Authors. obesity reviews © 2012 International Association for the Study of Obesity.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22863407     DOI: 10.1111/j.1467-789X.2012.01020.x

Source DB:  PubMed          Journal:  Obes Rev        ISSN: 1467-7881            Impact factor:   9.213


  11 in total

1.  Micronutrient status of individuals with overweight and obesity following 3 months' supplementation with PolyGlycopleX (PGX®) or psyllium: a randomized controlled trial.

Authors:  Sebely Pal; Jenny McKay; Suleen Ho; Monica Jane; Roland J Gahler; Simon Wood
Journal:  BMC Nutr       Date:  2022-05-03

Review 2.  Herbs with anti-lipid effects and their interactions with statins as a chemical anti- hyperlipidemia group drugs: A systematic review.

Authors:  Hojjat Rouhi-Boroujeni; Hamid Rouhi-Boroujeni; Esfandiar Heidarian; Fereshteh Mohammadizadeh; Mahmoud Rafieian-Kopaei
Journal:  ARYA Atheroscler       Date:  2015-07

3.  Effect on body weight and composition in overweight/obese Australian adults over 12 months consumption of two different types of fibre supplementation in a randomized trial.

Authors:  Sebely Pal; Suleen Ho; Roland J Gahler; Simon Wood
Journal:  Nutr Metab (Lond)       Date:  2016-11-17       Impact factor: 4.169

Review 4.  Microbial Regulation of Glucose Metabolism and Insulin Resistance.

Authors:  Silke Crommen; Marie-Christine Simon
Journal:  Genes (Basel)       Date:  2017-12-29       Impact factor: 4.096

5.  Effects of Higher Dietary Protein and Fiber Intakes at Breakfast on Postprandial Glucose, Insulin, and 24-h Interstitial Glucose in Overweight Adults.

Authors:  Akua F Amankwaah; R Drew Sayer; Amy J Wright; Ningning Chen; Megan A McCrory; Wayne W Campbell
Journal:  Nutrients       Date:  2017-04-02       Impact factor: 5.717

6.  Effect on Insulin, Glucose and Lipids in Overweight/Obese Australian Adults of 12 Months Consumption of Two Different Fibre Supplements in a Randomised Trial.

Authors:  Sebely Pal; Suleen Ho; Roland J Gahler; Simon Wood
Journal:  Nutrients       Date:  2017-01-29       Impact factor: 5.717

Review 7.  Gastrointestinal Transit Time, Glucose Homeostasis and Metabolic Health: Modulation by Dietary Fibers.

Authors:  Mattea Müller; Emanuel E Canfora; Ellen E Blaak
Journal:  Nutrients       Date:  2018-02-28       Impact factor: 5.717

8.  Effects of the Antiobesity Drugs Aplex and Venera on Certain Biochemical and Physiological Indices in Obese Adult Male Albino Rats.

Authors:  Suzan S A Elpasty; Eman G E Helal; Ashraf M M Algendy; Hany N Yousef
Journal:  Adv Pharmacol Pharm Sci       Date:  2022-04-11

Review 9.  CODEX-aligned dietary fiber definitions help to bridge the 'fiber gap'.

Authors:  Julie Miller Jones
Journal:  Nutr J       Date:  2014-04-12       Impact factor: 3.271

Review 10.  An Overview of Herbal Products and Secondary Metabolites Used for Management of Type Two Diabetes.

Authors:  Ajda Ota; Nataša P Ulrih
Journal:  Front Pharmacol       Date:  2017-07-06       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.